Cover - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Jul. 31, 2025 |
Oct. 15, 2025 |
Jan. 31, 2025 |
|
| Document Type | 10-K | ||
| Amendment Flag | false | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Period End Date | Jul. 31, 2025 | ||
| Document Fiscal Period Focus | FY | ||
| Document Fiscal Year Focus | 2025 | ||
| Current Fiscal Year End Date | --07-31 | ||
| Entity File Number | 001-40101 | ||
| Entity Registrant Name | BRIACELL THERAPEUTICS CORP. | ||
| Entity Central Index Key | 0001610820 | ||
| Entity Tax Identification Number | 47-1099599 | ||
| Entity Incorporation, State or Country Code | A1 | ||
| Entity Address, Address Line One | Suite 300 - 235 15th Street | ||
| Entity Address, City or Town | West Vancouver | ||
| Entity Address, State or Province | BC | ||
| Entity Address, Postal Zip Code | V7T 2X1 | ||
| City Area Code | (604) | ||
| Local Phone Number | 921-1810 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | true | ||
| Elected Not To Use the Extended Transition Period | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 94,477,705 | ||
| Entity Common Stock, Shares Outstanding | 1,883,906 | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| ICFR Auditor Attestation Flag | false | ||
| Auditor Firm ID | 1930 | ||
| Insider Trading Policies and Procedures Adopted [Flag] | true | ||
| Auditor Name | MNP LLP | ||
| Auditor Opinion [Text Block] | We
have audited the accompanying consolidated balance sheets of BriaCell Therapeutics Corp. (the Company) as at July 31, 2025 and 2024,
and the related consolidated statements of operations and comprehensive loss, changes in shareholders’ equity (deficit), and cash
flows for each of the years in the two-year period ended July 31, 2025, and the related notes (collectively referred to as the consolidated
financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position at the Company as of July 31, 2025 and 2024, and the results of its consolidated operations and its consolidated cash flows for each of the years in the two-year period ended July 31, 2025, in conformity with accounting principles generally accepted in the United States of America. |
||
| Auditor Location | Mississauga, Canada | ||
| Common shares, no par value | |||
| Title of 12(b) Security | Common shares, no par value | ||
| Trading Symbol | BCTX | ||
| Security Exchange Name | NASDAQ | ||
| Warrants to purchase common shares, no par value | |||
| Title of 12(b) Security | Warrants to purchase common shares, no par value | ||
| Trading Symbol | BCTXW | ||
| Security Exchange Name | NASDAQ | ||
| Warrants To Purchase Common Shares No Par Value One [Member] | |||
| Title of 12(b) Security | Warrants to purchase common shares, no par value | ||
| Trading Symbol | BCTXZ | ||
| Security Exchange Name | NASDAQ |